I'm Shawn M. Casey, DMD (Casey Dental, Pittston, PA). I'm not writing Ozempic scripts in my chair, but I do manage medication risk every day around oral surgery, sedation (nitrous + oral conscious sedation), healing, and infection--so my lens is: "Will this drug change what happens in the mouth, in the chair, and post-op?" For adults 60+, the big factors are dehydration/nutrition (GLP-1 nausea + reduced intake can wreck oral healing), aspiration risk if we're doing sedation (delayed gastric emptying matters), and whether they can maintain oral hygiene if they're fatigued or dizzy. A real-world example: an older implant-supported denture consult who's "not eating much lately" is a red flag for me--I'll coordinate timing with their prescriber because poor protein intake + dry mouth can turn routine healing into a mess. Why Ozempic isn't indicated for pediatrics but Wegovy is comes down to what the FDA approvals target: Ozempic is positioned for type 2 diabetes, Wegovy for chronic weight management, and the pediatric data/labeling lives on the weight-management product. Practically, when teens come in for orthodontic evals, I'm thinking growth, nutrition, enamel risk, and compliance--weight-loss meds that suppress appetite can indirectly increase cavity risk if the kid ends up grazing on easy carbs or sipping flavored drinks. If Ozempic is used off-label under 18 (not my call, but I've seen the downstream effects), the decision should be anchored to: confirmed diagnosis/severity, failed lifestyle-only attempts, family support, ability to follow up, and a plan to prevent dehydration + reflux + poor intake. For older adults off-label, I'd add: fall risk from dizziness, constipation/reflux worsening (acid + enamel is a bad combo), and whether upcoming dental surgery needs a pause/adjustment--guided implant surgery and extractions don't mix well with "I'm nauseated and can't keep fluids down."
Senior Consultant Cardiologist at Harley Street Heart & Vascular Centre
Answered 6 days ago
Hi Amelia, I'm Reginald Liew, Senior Consultant Cardiologist at Harley Street Heart & Vascular Centre and I can comment on clinical safety considerations for GLP-1 agonists in older adults. For patients 60 and over I emphasise a baseline eye exam, conservative A1C targets to avoid rapid glucose drops, and close follow-up with primary care, endocrinology and ophthalmology, especially during the first 12 to 18 months. I cannot speak to regulatory labeling differences between Ozempic and Wegovy, but from a clinical standpoint the main concerns are the pace of glucose change and potential eye effects, so monitoring and individualized assessment are key. When off-label use in under-18s is considered, the factors that would guide me are the likelihood of rapid A1C change, the need for baseline and repeat eye assessment, and multidisciplinary support for monitoring. For off-label use in older adults I would use the same precautions, tailor the approach to each patient's unique risk factors and ability to attend close follow-up, and I can share further clinical examples on request. Kind regards, Reginald Liew, Senior Consultant Cardiologist.
I don't manage Ozempic prescriptions much, though I use both modern and traditional medicine. For patients over 60, I'm cautious. Their metabolism slows down and organ function changes, so you have to assess that carefully. Most doctors avoid Ozempic for anyone under 18 since the long-term effects are unknown. Wegovy has the research for that age group, so that's different. If I'm considering it off-label for an older patient, I review their entire health profile and start slow to watch for any sensitivities. If you have any questions, feel free to reach out to my personal email
I don't prescribe Ozempic often, but I see older patients taking it before surgery. Their doctors are usually careful about kidney and heart risks. I don't treat kids, but specialists seem to avoid Ozempic for them. They prefer Wegovy because it has the safety data for younger people, while Ozempic just doesn't have the research for that age group yet. If you have any questions, feel free to reach out to my personal email
Founder & Medical Director, Board-Certified OB/GYN & Reproductive Endocrinologist at Aurea Fertility Center
Answered 6 days ago
When I see patients over sixty, I check their kidneys, liver, heart, and current meds before suggesting Ozempic. It keeps blood sugar steady, but the nausea and hypoglycemia risk mean I watch them closely. I wont prescribe it to kids off-label. Wegovy has the pediatric trials to back it up, but Ozempic just doesnt have enough research on kids yet. I stick to what we know works. If you have any questions, feel free to reach out to my personal email
Hi Amelia, I'm Amir Husen, Content Writer, SEO Specialist & Associate at ICS Legal; I have written about semaglutide drugs such as Rybelsus and about safety and mobility issues for older adults, so I can speak to prescribing considerations and product positioning. From that coverage, clinicians weighing semaglutide use in adults 60+ commonly consider comorbidities, mobility and fall risk, existing heart or joint conditions, and the patient's goals, and they note that side effects tend to be similar across semaglutide agents. My work also highlights that some semaglutide products are positioned differently—Rybelsus is framed around type 2 diabetes while agents used for obesity management, like Wegovy, are often preferred for weight loss—so labeling and intended use influence pediatric versus adult choices. When clinicians consider off-label use in patients under 18 or in older adults, reporting shows they focus on those same safety factors, the availability of approved alternatives, and individual risk-benefit assessments. I can share relevant excerpts from my reporting if that would help your piece. Best regards, Amir Husen